Natera Posts First Ever 1-Million-Unit Quarter, Raises Full-Year Revenue Guide by $120 Million as Oncology Growth Hits Record Pace
Q1 2026 Earnings Call, May 7, 2026 — Revenue Beats Drive Meaningful Guidance Reset Across Revenue and Margins
Natera delivered one of its strongest quarters on record in Q1 2026, reporting revenues of $697 million, a 39% year-over-year increase, and crossing a historic operational threshold: one million units processed in a single quarter. The company used the momentum to fully reset its full-year revenue guidance upward by more than $120 million at the midpoint while simultaneously raising gross margin guidance to 65%. The combination of accelerating oncology volumes, a successful new product launch in women's health, and continued progress on average selling prices paints a picture of a business that is, by most measures, operating ahead of plan.
Oncology Volume Inflects Higher — And the Acceleration Is Broadening
The most consequential data point from the quarter was Signatera's oncology volume. Natera processed 249,000 clinical oncology units in Q1, representing 55% year-over-year growth and a sequential increase of roughly 24,000 units over Q4 2025 — the largest quarterly unit addition the company has ever achieved. CEO Steve Chapman was direct: "This is the biggest increase we've ever achieved." What is notable is not just the magnitude but the breadth of the drivers behind it.
Growth in Q1 was supported by a dense cadence of clinical data releases in the second half of 2025, spanning bladder, breast, colorectal, uterine, testicular and lymphoma cancers. The bladder cancer data, presented at ESMO and subsequently published in the New England Journal of Medicine, was cited as a particularly meaningful catalyst, with Chapman noting that clinical data always takes time to translate into behavioral changes at the physician level and that the volume impact from that publication is still being felt. An integration launched with OncoEMR across 4,500 physicians created a more seamless ordering experience, and additional commercial reps hired in 2025 are now contributing, though Chapman estimated they are only 50% to 75% ramped. The implication is that there is still a meaningful tailwind from these reps becoming fully productive over the coming quarters.
The acquisition of Foresight Diagnostics, closed in Q4 2025, is also beginning to show up in the numbers. Foresight's deep research and clinical relationships in hematology have served as a tailwind for Signatera adoption, with hematologists increasingly ordering Signatera MRD for lymphoma patients. Biopharma interest in the phased variant technology platform acquired through Foresight has been picking up meaningfully in both hematology and solid tumors. Solomon Moshkevich, President of Clinical Diagnostics, confirmed that at least one major pharma-sponsored trial leveraging phase variant technology has already been contracted but not yet publicly announced.
Signatera ASP Trajectory Remains a Significant Earnings Driver
Signatera average selling prices reached approximately $1,250 in Q1, another sequential increase of roughly $25 over Q4 2025. The pathway to getting there included better alignment with smaller Medicare Advantage plans, more consistent reimbursement for covered services under biomarker state initiatives, and a favorable update to CMS bundled pricing announced at the start of the year. The bundled pricing change did create a temporary delay in cash collections as Natera had to reload updated prices across all payers and revalidate engineering systems — a process that pushed DSOs modestly higher in Q1. CFO Mike Brophy confirmed those delayed cash receipts arrived in April, and collections are now back on track.
The company's updated full-year guidance implies Signatera exits 2026 at roughly $1,275 ASP, up from a prior target that assumed $50 in gains for the year. Brophy was careful to note that the company believes it can reach $1,275 without additional coverage decisions from MolDX — meaning new coverage approvals would represent upside to the guide. Natera has approximately seven additional histology submissions currently in review with MolDX, and Chapman indicated these have already gone through one round of back-and-forth. Chapman framed the potential plainly: "These ones that are in submission right now would make up the vast majority of the sort of remaining noncovered business for us." The long-term Signatera ASP target remains $2,000. At current annualized volumes, reaching that target would generate an additional $750 million in revenue and gross profit annually.
The TOMR Paradigm Is Becoming Natera's Most Important Strategic Narrative
Perhaps the most intellectually significant portion of the call was Moshkevich's detailed articulation of the treatment-on-molecular-recurrence, or TOMR, framework. TOMR describes a new clinical paradigm in which MRD results — rather than radiological scans — are used to trigger or withhold systemic therapy. The concept is now being tested across multiple active pharma-sponsored trials including ALPHA3 in large B-cell lymphoma, STELLAR-316 in colorectal cancer, DARE and Treat ctDNA in breast cancer, and IMvigor011 in bladder cancer.
The ALPHA3 interim analysis, sponsored by Allogene Therapeutics, provided striking data. In patients with large B-cell lymphoma who were MRD-positive following frontline therapy, a second-line experimental treatment achieved MRD clearance in 58% of the treatment arm versus 17% in the observation arm — a 41-point absolute delta. Median ctDNA levels decreased 98% from baseline in the treatment arm while increasing 27% in the observation arm. The trial's positive interim futility analysis was predicated on MRD clearance as an endpoint, reinforcing the concept that molecular response can serve as a meaningful proxy for clinical outcomes.
The IMvigor011 bladder cancer trial added a compelling economic dimension to the TOMR story. Forty-seven percent of patients in that trial were persistently MRD-negative over the first year and avoided adjuvant systemic therapy entirely, achieving a two-year overall survival rate of 97%. Moshkevich noted that a course of adjuvant immunotherapy can cost around $196,000 per year, and that withholding it in approximately half of bladder cancer patients based on MRD-negative status represents enormous value to patients and payers alike. He further argued that even with the emergence of perioperative EV-pembro combinations in bladder cancer, physicians are signaling they would consider withholding the EV component — estimated to cost over $100,000 per patient — in MRD-negative patients after surgery.
The economic case for colorectal cancer is also building, with two health economic studies from Blue Shield and U.K. insurer Bupa independently demonstrating that MRD-guided treatment in Stage II and Stage III colorectal cancer can reduce system-level costs by 21% to 43%. This kind of payer-level data is precisely what drives reimbursement decisions, and Natera is generating it at scale across multiple tumor types.
Surgery Avoidance Emerges as a New and Potentially Powerful Clinical Use Case
A distinct and underappreciated theme from the quarter is the emerging body of evidence suggesting Signatera can help patients avoid major surgery altogether. In bladder cancer, data presented at ASCO GU showed that MRD-negative patients who forewent cystectomy had outcomes comparable to those who underwent surgery, with investigators concluding that "ctDNA-negative patients may avoid immediate cystectomy." In rectal cancer, a paper published in the journal Cancers showed that MRD-negative patients after neoadjuvant therapy who chose to avoid surgery had excellent outcomes. In breast cancer, a Clinical Cancer Research publication showed that women over 70 with early-stage ER-positive disease who tested MRD-negative at diagnosis were able to forgo surgery and remain progression-free. Moshkevich summarized the broader implication: "MRD testing is not only about finding recurrence earlier. It can also help avoid overtreatment, including major surgeries as well as systemic therapy." All three indications are already covered by Medicare for Signatera.
Fetal Focus Launch Running Ahead of Expectations
In women's health, Natera's launch of Fetal Focus, a next-generation single-gene NIPT that enables direct assessment of fetal cell-free DNA across 21 genes associated with serious early-onset conditions, is tracking well above initial expectations. The company is approaching an annualized run rate of approximately 200,000 Fetal Focus orders. Notably, Natera does not include Fetal Focus orders in its standard test-processed count when Horizon screens negative for one of the 21 conditions — meaning the reported women's health unit growth of approximately 63,000 sequential units between Q4 2025 and Q1 2026 is almost entirely attributable to the core Panorama and Horizon business. Including the majority of Fetal Focus orders would push reported volumes materially higher.
The EXPAND trial, a prospective blinded multicenter study with genetic outcomes on all participants, was selected for an oral plenary presentation at the Society for Maternal-Fetal Medicine Meeting — described as a rare distinction — and results have been submitted for peer-reviewed publication. The clinical data is supporting new account wins and strong client retention, and Natera characterized the launch as exceeding expectations on both the commercial and scientific fronts.
FIND CRC Enrollment Ahead of Schedule — 2027 FDA Submission Path Firming Up
Natera's colorectal cancer early detection study, FIND CRC, is enrolling above plan. The study targets approximately 25,000 to 40,000 average-risk adults and is now on pace to complete enrollment for the PMA submission in Q3 2026, supporting a 2027 FDA PMA readout. The company had previously demonstrated 22.5% sensitivity for advanced adenomas at 91.5% specificity in the PROCEED-CRC study, with nearly all detected lesions under 30 millimeters — a particularly challenging detection cohort for blood-based assays.
Natera is positioning colorectal cancer screening as the first step in a broader early detection platform, with plans to develop a multi-cancer early detection assay over time. The faster-than-anticipated enrollment pace is what prompted the company to raise R&D guidance by $50 million — the incremental spend is being directed toward pulling forward FIND CRC and additional MRD interventional trials that have become newly available. Brophy framed the R&D spend increase as a high-return deployment: "We have a long track record of generating high ROICs in our R&D effort, and our plan is to stay ambitious to maintain our leadership position."
Japan Launch Could Structurally Expand the Signatera TAM
Japan is emerging as a potentially significant near-term volume catalyst. PMDA regulatory approval remains on track for Q2 2026, with commercial launch preparations advancing for a broad rollout shortly after. Japan diagnoses a similar absolute number of colorectal cancer cases annually as the United States, and Natera estimates that a successful CRC launch alone could effectively double Signatera's annual CRC volume TAM. Natera has meaningful commercial infrastructure already in place: Signatera has been used across more than 150 institutions through the CIRCULATE-Japan and Galaxy trials, giving hundreds of oncologists firsthand experience before commercialization begins. Both JSMO and JSCO have issued supportive clinical practice guidelines for MRD testing. Japan's single national payer structure is also favorable — one positive reimbursement decision creates broad national access. Natera has indicated that muscle invasion bladder cancer will be the next prioritized indication after CRC, given the IMvigor011 data.
Gross Margin Dynamics: Clean Underlying Trends, Two Transient Headwinds
Q1 gross margins came in at just under 65%, exceeding the 64% midpoint the company guided to in February. However, the headline figure masked an approximately 2 percentage point headwind from two factors that Natera characterized as transient. First, a larger-than-usual stock-based compensation charge to cost of goods sold stemmed from the close of the Foresight acquisition. Second, and more impactful, was the elevated work-in-process in the lab at quarter end. Natera recognized revenue on only 92% of cases received in Q1 versus a normalized rate of 95% to 96%, meaning a significant bolus of cases absorbed COGS but generated no revenue in the period. Brophy estimated this accounted for approximately 1.5 percentage points of gross margin headwind. The dynamic was driven by exceptionally high volumes arriving late in the quarter — a favorable signal for forward volumes but a mechanical drag on Q1 reported margins. Brophy characterized both factors as resolving in subsequent quarters, and Natera raised its full-year gross margin guidance to 65% at the midpoint, with the Q1 actuals now baked into the annual number.
On SG&A, the line was elevated relative to Q4 2025 as a percentage of revenue. Brophy attributed this to approximately $25 million in Q1-specific items including typical seasonal sales and marketing expenses and noncash balance sheet adjustments, the majority of which do not repeat. With those backed out, the company held SG&A guidance steady, consistent with its stated commitment to operating leverage while remaining opportunistic on high-return growth investments.
ASCO 2026 Will Be a Broad Evidence Statement, Not a Single Data Point
Natera will present 35 abstracts at ASCO 2026, spanning TOMR, pan-cancer MRD, phase variant technology, real-world evidence and trials in progress across colorectal, bladder, breast, lung, lymphoma, melanoma, ovarian, uterine, sarcoma and other tumor types. The headline presentation is a pan-cancer MRD meta-analysis covering 18 published studies, more than 3,000 patients and 15 solid tumor types, in which ctDNA positivity was strongly associated with recurrence risk in both the MRD and surveillance settings. Chief Medical Officer Alexey Aleshin framed the significance plainly: this moves the conversation "beyond individual tumor type wins to a broader platform-level statement." The scale of 35 abstracts at a single meeting is itself a signal of the depth of the evidence base Natera is accumulating — and the barrier to entry it is constructing for competitors attempting to build a comparable data set.
Natera, Inc. Deep Dive
The Business Engine: Molecular Insights at Scale
Natera operates at the frontier of precision medicine, utilizing advanced cell-free DNA testing platforms to provide non-invasive, molecular-level diagnostics across three core verticals: women's health, oncology, and organ health. The foundational business model rests on designing proprietary, highly sensitive diagnostic tests that inform critical clinical decisions. Rather than selling diagnostic equipment, Natera operates as a clinical laboratory, processing blood samples sent by physicians and billing insurance providers, government payers, and biopharma partners. The scale of this operation is staggering. As of early 2026, the company is processing over 1 million tests per quarter, effectively translating its laboratory throughput into a recurring revenue stream underpinned by clinical utility. This volume throughput generated $2.3 billion in revenue in 2025, and current guidance points to an impressive $2.74 billion to $2.82 billion for 2026, making Natera a formidable revenue engine in a sector historically plagued by sub-scale commercial execution.
The company's product suite is anchored by three flagship offerings. In women's health, Panorama is a non-invasive prenatal test that screens for chromosomal abnormalities, utilizing Natera's proprietary single-nucleotide polymorphism technology. In oncology, Signatera is a personalized, tumor-informed molecular residual disease test used to detect circulating tumor DNA after surgery, enabling oncologists to identify cancer recurrence months earlier than standard imaging. In the organ health segment, Prospera is a cell-free DNA test that assesses the risk of organ transplant rejection. While women's health provides a massive, stable volume base, it is the oncology franchise, led by Signatera, that has transformed Natera's financial profile. Signatera represents a high-value, high-margin, longitudinal testing annuity. Because it monitors recurrence over time, a single cancer patient generates multiple test orders throughout their survivorship journey, creating a compelling unit economic model driven by recurring test volumes rather than one-off screening events.
Market Position and Competitive Dynamics
Natera holds a commanding position across its primary end-markets, successfully displacing legacy approaches and capturing significant market share from established incumbents. In the non-invasive prenatal testing space, Panorama holds an estimated 35% to 45% of the domestic market, making Natera the undisputed top-tier provider alongside large national reference laboratories like LabCorp and Quest Diagnostics. However, Natera's true competitive battleground is the fast-growing minimal residual disease segment. Here, the end-customers are clinical oncologists and massive biopharma companies conducting clinical trials. The minimal residual disease market is intensely competitive, with Natera facing off against Exact Sciences, Guardant Health, and Foundation Medicine. Despite this formidable peer group, Natera has established Signatera as the category leader in tumor-informed testing, capturing the lion's share of testing volumes, which surged by 55% year-over-year in the first quarter of 2026 to reach nearly 250,000 clinical oncology units.
In the organ health market, the competitive dynamics are similarly aggressive. Natera's Prospera directly challenges CareDx's AlloSure, the legacy incumbent in transplant rejection monitoring. By aggressively investing in clinical utility data, such as the DEFINE-HT and PEDAL trials, Natera has steadily eroded CareDx's market share in key academic transplant centers. What unifies Natera's strategy across these distinct verticals is its approach to payer dynamics. The ultimate gatekeeper to revenue in the diagnostics space is the payer, specifically Medicare and large commercial health insurers. By continuously funding extensive, peer-reviewed clinical utility studies, Natera has successfully secured broad Medicare coverage and favorable pricing, shielding its market share from sub-scale competitors who lack the capitalization to fund equivalent data generation.
Competitive Advantages: The Tumor-Informed Moat
The core of Natera's competitive moat lies in its differentiated technological approach to cell-free DNA analysis. While many competitors utilize a tumor-naive approach, meaning they use a standardized panel to look for common cancer mutations in a patient's blood, Natera champions a tumor-informed methodology. When a patient undergoes surgery to remove a tumor, Natera sequences the actual tumor tissue, identifies its unique mutational signature, and builds a custom, personalized blood test for that specific patient. This bespoke approach yields extraordinary clinical sensitivity and specificity, drastically reducing false positives while detecting recurrent cancer at miniscule fractions of circulating tumor DNA. This strategy essentially creates a closed-loop system for every patient. Once an oncologist establishes a baseline with Signatera's custom assay, switching the patient to a competitor's off-the-shelf test for subsequent monitoring introduces clinical risk, creating an immensely sticky product architecture.
This technological advantage is heavily reinforced by an economic and data-driven flywheel. As test volumes cross the 1 million mark per quarter, Natera benefits from massive economies of scale. These efficiencies are clearly visible in the company's margin profile, with gross margins climbing to approximately 65% in the first quarter of 2026. High throughput lowers the per-unit cost of sequencing, generating gross profits that can be continually recycled into massive clinical trials. With over 400 peer-reviewed publications backing its assays, Natera's clinical evidence repository acts as a nearly insurmountable barrier to entry for smaller diagnostic upstarts. The commercial infrastructure required to match Natera's sales force, coupled with the capital required to replicate its clinical validation data, creates a deeply entrenched defensive position.
Industry Dynamics: Opportunities and Threats
The broader cell-free DNA testing industry is benefiting from structural tailwinds as medical guidelines universally adopt molecular diagnostics as standard-of-care. Oncology is undergoing a paradigm shift from late-stage treatment to early recurrence detection, driving explosive volume growth for minimal residual disease assays. The market is projected to reach over $22 billion by the early 2030s, and precision medicine is no longer a niche research tool but a vital clinical necessity. Health systems and payers increasingly recognize that spending several thousand dollars on a diagnostic test that guides precision therapy is vastly more cost-effective than blindly administering expensive, toxic chemotherapies to patients who may not need them, or worse, missing early recurrences when they are most curable.
However, the industry faces material regulatory and pricing headwinds that threaten to compress margins. The most significant structural threat is the Food and Drug Administration's final rule regarding the oversight of Laboratory Developed Tests. This phased-in regulatory framework requires diagnostic companies to comply with stringent medical device reporting, quality system requirements, and eventually, pre-market review for tests that historically operated with minimal FDA friction. While this increases the regulatory burden and compliance costs for Natera, it ironically serves to widen the competitive moat. Small, undercapitalized laboratories will struggle to absorb the multi-million dollar compliance costs, driving industry consolidation. Furthermore, ongoing pricing pressure from national labs in the commoditized reproductive testing segment, alongside the perennial threat of Medicare reimbursement cuts, necessitates constant vigilance from Natera to protect its average selling prices through continual product innovation and definitive clinical utility data.
Growth Drivers: Next-Generation Assays and Expansion
To sustain its aggressive revenue trajectory, Natera has launched a wave of next-generation products aimed at expanding its clinical indications and increasing its average selling price. In women's health, the recent launch of Fetal Focus, an expanded 21-gene single-gene prenatal test, has been a major catalyst. Approaching an annualized run rate of 200,000 orders shortly after launch, Fetal Focus demonstrates the company's ability to drive rapid adoption of higher-value diagnostic panels within its established obstetrician network. Concurrently, the rollout of the Signatera Genome assay pushes the boundary of sensitivity even further in the oncology space, supporting an upward march in the product's average selling price, which recently crossed $1,250 per test.
The most transformative growth catalyst, however, is Natera's $450 million acquisition of Foresight Diagnostics in late 2025. This strategic masterstroke brought Foresight's patented PhasED-Seq technology in-house. PhasED-Seq requires the detection of at least two separate mutations on the same DNA molecule, effectively reducing sequencing errors and achieving an astonishing limit of detection of 0.1 parts per million. This acquisition catapults Natera into the ultra-sensitive testing tier, completely outflanking competitors relying on first-generation liquid biopsy methods. Crucially, it accelerates Natera's expansion into the lucrative hematologic oncology market, specifically B-cell lymphomas, where Foresight had established a leadership position. By integrating this phased variant technology into the broader Signatera platform for clinical use in 2026, Natera is actively defending its sensitivity crown while unlocking massive new addressable markets.
The Disruption Horizon: New Entrants and Alternative Technologies
While Natera dominates the tumor-informed segment, the primary disruptive threat comes from advancements in tumor-naive technologies. Companies like Guardant Health, and heavily funded AI-driven new entrants like Tempus AI and Freenome, are aggressively iterating on blood-only diagnostics. The tumor-naive value proposition is compelling: by eliminating the need to secure, slice, and sequence physical tumor tissue, turnaround times are vastly shorter, and the logistics are substantially less complex. Historically, the trade-off for this speed was a significant drop in sensitivity. However, as these competitors apply deep learning, artificial intelligence, and multi-omic analysis combining epigenetics and proteomics to blood samples, the sensitivity gap is narrowing.
If a well-capitalized disruptor can successfully demonstrate that a purely blood-based, off-the-shelf assay matches the sensitivity and specificity of Natera's custom-built Signatera test, Natera's operational complexity could transition from a competitive advantage to a cumbersome liability. This is the existential debate in precision oncology. Natera's management is acutely aware of this threat, which precisely explains the Foresight Diagnostics acquisition. By lowering the limit of detection to a level currently unreachable by tumor-naive approaches, Natera is forcing disruptors to chase an accelerating target. While no new entrant currently possesses a clinical data package robust enough to unseat Signatera in the short term, the rapid convergence of artificial intelligence and low-cost sequencing means the threat of disruption remains a permanent fixture on the horizon.
Management Track Record
Under the leadership of Chief Executive Officer Steve Chapman and Chief Financial Officer Mike Brophy, Natera's management team has executed with clinical precision over the past several years. Their tenure has been defined by a relentless focus on scaling test volumes, driving clinical validation, and ruthlessly pursuing margin expansion. The results speak for themselves: Natera has evolved from a cash-burning diagnostic enterprise into a cash-flow positive machine at immense scale. Achieving positive cash inflow in the first quarter of 2026 while simultaneously processing over 1 million tests in a single quarter is a monumental operational feat that eludes the vast majority of medical diagnostic companies.
Furthermore, management's capital allocation has been exceptionally shrewd. Rather than diluting focus with disparate acquisitions, they have concentrated investments directly into their core competencies. The deployment of capital to fund massive prospective trials has successfully secured the payer coverage necessary to drive top-line revenue, while operational leverage and cost-of-goods-sold improvements have structurally elevated gross margins from the low 50% range a few years ago to 65% today. The timely acquisition of Foresight Diagnostics further underscores a management team that accurately anticipates technological shifts and acts decisively to secure the intellectual property needed to protect the company's long-term terminal value. Their track record instills deep confidence in their ability to navigate the complex regulatory and competitive challenges ahead.
The Scorecard
Natera stands as a dominant force in the rapidly expanding precision diagnostics sector, operating a highly successful business model that translates vast clinical utility into recurring, high-margin revenue. The company's competitive moat is deeply entrenched, fortified by the structural advantages of a tumor-informed approach, an unmatched repository of peer-reviewed clinical evidence, and a massive scale that drives favorable unit economics. The strategic acquisition of Foresight Diagnostics ensures that Natera remains at the absolute bleeding edge of assay sensitivity, directly neutralizing the emerging threats posed by next-generation tumor-naive competitors. Furthermore, management's flawless execution in expanding gross margins and steering the enterprise into positive cash flow generation provides a profound level of financial resilience.
While the broader industry faces headwinds from pricing pressures and increased regulatory scrutiny under the new FDA laboratory-developed test framework, Natera's scale and pristine balance sheet uniquely position it to absorb these compliance costs and capture further market share as sub-scale competitors capitulate. The long-term growth algorithm remains robust, driven by the ongoing paradigm shift toward minimal residual disease monitoring in oncology and expanding indications in women's and organ health. In a complex, highly competitive healthcare landscape, Natera has structurally engineered a durable, high-growth clinical monopoly that is fundamentally reshaping the standard of care.